Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
8.14
+0.23 (2.91%)
At close: Jul 30, 2026, 4:00 PM EDT
8.11
-0.03 (-0.37%)
After-hours: Jul 30, 2026, 7:52 PM EDT
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
504.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Valneva SE | 180.25M |
| Ginkgo Bioworks Holdings | 151.40M |
| 4D Molecular Therapeutics | 88.24M |
| Assembly Biosciences | 71.10M |
| Verastem | 49.59M |
| Adlai Nortye | 5.00M |
| Artiva Biotherapeutics | 251.00K |
HELP News
- 3 days ago - Helus Pharma initiated with an Overweight at Wells Fargo - TheFly
- 9 days ago - Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 - TheFly
- 9 days ago - Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule - GlobeNewsWire
- 13 days ago - Helus Pharma price target lowered to $45 from $48 at Guggenheim - TheFly
- 16 days ago - Helus Pharma price target lowered to $15 from $30 at Alliance Global - TheFly
- 21 days ago - Psychedelic: Compass Pathways reports six-month data for psilocybin drug - TheFly
- 21 days ago - Helus Pharma price target lowered to $70 from $95 at H.C. Wainwright - TheFly
- 4 weeks ago - Helus Pharma price target lowered to $42 from $45 at Canaccord - TheFly